TVRD Share Price Performance
US$4.02
-14.23 (-77.97%)
Price US$4.02
Share Pricen/a
Tvardi Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
TVRD Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Tvardi Therapeutics, Inc. Key Details
About TVRD
- Founded
- 2017
- Employees
- 12
- CEO
- WebsiteView website
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
